Sorafenib is a protein tyrosine kinase inhibitor approved for use in the treatment of renal cell carcinoma, and it has also received attention for its ability to sensitize tumor cells to TRAIL-mediated apoptosis by shifting the intracellular ratio of pro-apoptotic and anti-apoptotic molecules [65]. This evidence concerns the gene TNFSF10 and neoplasm.